PureTech Health plc (LSE:PRTC) hired Joep Muijrers as CFO. He was a partner and portfolio manager at Life Sciences Partners.
PureTech is developing products to treat nervous, immune and gastrointestinal system dysfunction. At its inaugural Brain, Immune, Gut (BIG) Axis Summit in January, the company said it plans to use its Glyph technology -- licensed from Monash University last year -- to explore using the lymphatic system to transport and distribute therapeutics (see BioCentury, March 22).
Last month, the company raised £72 million ($100 million) in a placement underwritten by Jefferies and Peel Hunt (see BioCentury Extra, March 13).
PureTech added 0.50p to 150.50p on Tuesday.